|
Apr 15
|
Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
|
|
Apr 15
|
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
|
|
Apr 14
|
Transactions in Connection with Share Buy-back Program
|
|
Apr 10
|
Genmab A/S Share Capital Reduction
|
|
Mar 31
|
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
|
|
Mar 31
|
Transactions in connection with share buy-back program
|
|
Mar 27
|
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
|
|
Mar 25
|
Genmab Announces Initiation of Share Buy-Back Program
|
|
Mar 12
|
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
|
|
Mar 12
|
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
|
|
Mar 12
|
Passing of Genmab A/S’ Annual General Meeting
|
|
Mar 11
|
Genmab says J&J not exercising option on HexaBody-CD38
|
|
Mar 10
|
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
|
|
Feb 20
|
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
|
|
Feb 19
|
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
|
|
Jan 3
|
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|